Major differences between eGFR based on cystatin C compared with creatinine were associated with higher rates for all-cause mortality, CV events and kidney failure for outpatients, according to data ...

First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment —— Savolitinib ...

(Alliance News) - Hutchmed China Ltd on Wednesday said the results from its SACHI phase-three lung cancer trial have been published in medical journal the Lancet.

The conference held in Odisha marked 60 years (diamond jubilee) of the Indian Association of Pediatric Surgeons (IAPSCON).